FTC Sues Three Largest PBMs Alleging Rebating System Inflated Insulin Prices
- September 20, 2024
The Federal Trade Commission (FTC) filed suit September 20 against the three largest pharmacy benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) alleging they engaged in unfair methods of competition and unfair acts or practices under Section 5 of the FTC Act that have incentivized manufacturers to inflate the list price of insulin drugs, restricted patients’ access to lower list price products, and shifted the cost of high insulin list prices to vulnerable patients.
ARTICLE TAGS
You must be logged in to access this content.